Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-246-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.13 million
Profitability
Miscellaneous
Employees324
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions
What is Portola Pharmaceuticals' stock symbol?
Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."
How were Portola Pharmaceuticals' earnings last quarter?
Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.05) by $0.13. The biopharmaceutical company earned $28.42 million during the quarter, compared to the consensus estimate of $25.42 million. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. Portola Pharmaceuticals's revenue was up 608.7% compared to the same quarter last year. During the same period last year, the firm earned ($1.61) earnings per share. View Portola Pharmaceuticals' Earnings History.
When is Portola Pharmaceuticals' next earnings date?
What price target have analysts set for PTLA?
7 Wall Street analysts have issued 1-year target prices for Portola Pharmaceuticals' shares. Their forecasts range from $35.00 to $45.00. On average, they expect Portola Pharmaceuticals' share price to reach $40.83 in the next year. This suggests a possible upside of 48.8% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals.
What is the consensus analysts' recommendation for Portola Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals.
What are Wall Street analysts saying about Portola Pharmaceuticals stock?
Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (10/9/2019)
- 2. William Blair analysts commented, "We are encouraged by the continued growth of Andexxa, particularly with 74% of sales in the quarter coming from hospitals reordering Andexxa. In addition, management commentary continues to be positive, highlighting the increased utilization trends with current accounts, recent increase in CMS NT AP reimbursement level (to 65% from 50%), access to the Veterans Administration health system, and first sales in Europe. We believe there is continued long- term momentum for Andexxa beyond the addition of new accounts over the next several quarters, including strong growth of the factor Xa class, label expansion to include urgent surgery and enoxaparin, and continued guidance recommendations including the recent Joint Commission updates." (8/9/2019)
- 3. Cowen Inc analysts commented, "We look forward to the first in human data using the “Process B” and believe its use of higher cell doses, transduction enhancers, and commercial-grade vectors will promote higher VCN (≥1) resulting in more clinically meaningful outcomes." (5/8/2019)
Has Portola Pharmaceuticals been receiving favorable news coverage?
Media coverage about PTLA stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Portola Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Portola Pharmaceuticals.
Who are some of Portola Pharmaceuticals' key competitors?
Some companies that are related to Portola Pharmaceuticals include SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), United Therapeutics (UTHR) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Portola Pharmaceuticals own?
Who are Portola Pharmaceuticals' key executives?
Portola Pharmaceuticals' management team includes the folowing people:
- Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
- Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
- Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
- Cara Miller, VP of Investor Relations and Corp. Communications
- Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)
Who are Portola Pharmaceuticals' major shareholders?
Portola Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.70%), Patten & Patten Inc. TN (0.05%), CIBC Private Wealth Group LLC (0.02%), Hartwell J M Limited Partnership (0.02%) and Arden Trust Co (0.01%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Henry Ward Wolff, Hollings Renton, Jeffrey W Bird, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.
Which major investors are buying Portola Pharmaceuticals stock?
PTLA stock was bought by a variety of institutional investors in the last quarter, including Patten & Patten Inc. TN, CIBC Private Wealth Group LLC, Peregrine Capital Management LLC, Hartwell J M Limited Partnership and Arden Trust Co. View Insider Buying and Selling for Portola Pharmaceuticals.
How do I buy shares of Portola Pharmaceuticals?
Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Portola Pharmaceuticals' stock price today?
One share of PTLA stock can currently be purchased for approximately $27.45.
How big of a company is Portola Pharmaceuticals?
Portola Pharmaceuticals has a market capitalization of $1.88 billion and generates $40.13 million in revenue each year. The biopharmaceutical company earns $-350,220,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.View Additional Information About Portola Pharmaceuticals.
What is Portola Pharmaceuticals' official website?
How can I contact Portola Pharmaceuticals?
Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]
MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
